

**ASX ANNOUNCEMENT**

**22 May 2025**

## **Results of 2025 Annual Meeting of Stockholders**

**Sunnyvale, California; 22 May 2025:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), refers to the Annual Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

**ENDS**

***This announcement has been authorised for release by the EBR Systems Routine Notifications Committee, a committee established by the Board of Directors.***

**For more information, please contact:**

**Company**

Gary Doherty  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

**Investors**

Harry Halstead  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

**About EBR Systems**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

**EBR Systems’ WiSE Technology**

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for

our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

#### **Foreign Ownership Restriction**

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)		
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain
Item 1(a) Re-election of Class I Director - Mr Allan Will	Ordinary	203,991,698 99.99%	0 0.00%	0 0.00%	29,000 0.01% (Withheld)	203,991,698 99.99%	0 0.00%	29,000 0.01% (Withheld)
Item 1(b) Re-election of Class I Director - Mr Trevor Moody	Ordinary	203,753,576 99.87%	0 0.00%	0 0.00%	267,122 0.13% (Withheld)	203,753,576 99.87%	0 0.00%	267,122 0.13% (Withheld)
Item 2 Ratification and approval of prior issue of securities	Ordinary	177,908,455 99.56%	389,927 0.22%	0 0.00%	384,770 0.22%	177,908,455 99.56%	389,927 0.22%	384,770 0.22%
Item 3 Approval of amendment to 2021 Equity Incentive Plan and the issue of securities under the amended 2021 Equity Incentive Plan	Special	173,704,279 99.08%	1,256,164 0.72%	0 0.00%	343,905 0.20%	173,704,279 99.08%	1,256,164 0.72%	343,905 0.20%
Item 4 Approval of grant of Options to Mr John McCutcheon, President, CEO and Executive Director of the Company	Ordinary	174,056,565 99.29%	858,414 0.49%	0 0.00%	389,369 0.22%	174,056,565 99.29%	858,414 0.49%	389,369 0.22%
Item 5 Approval of grant of Options to Mr Allan Will, Executive Chair of the Company	Ordinary	173,621,565 99.04%	1,293,414 0.74%	0 0.00%	389,369 0.22%	173,621,565 99.04%	1,293,414 0.74%	389,369 0.22%
Item 6 Grant of Options to Ms Karen Dresler, Non-Executive Director of the Company	Ordinary	173,440,749 98.94%	1,422,730 0.81%	0 0.00%	440,869 0.25%	173,440,749 98.94%	1,422,730 0.81%	440,869 0.25%
Item 7 Approval of grant of Options to Mr Trevor Moody, Non-Executive Director of the Company	Ordinary	173,468,299 98.95%	1,420,180 0.81%	0 0.00%	420,869 0.24%	173,468,299 98.95%	1,420,180 0.81%	420,869 0.24%
Item 8 Approval of grant of Options to Dr David Steinhaus, Non-Executive Director of the Company	Ordinary	173,440,749 98.94%	1,422,730 0.81%	0 0.00%	440,869 0.25%	173,440,749 98.94%	1,422,730 0.81%	440,869 0.25%
Item 9 Approval of grant of Options to a holding nominated by Dr Bronwyn Evans, Non-Executive Director of the Company	Ordinary	202,177,099 99.09%	1,420,490 0.70%	0 0.00%	423,109 0.21%	202,177,099 99.09%	1,420,490 0.70%	423,109 0.21%
Item 10 Approval of grant of Options to a nominated entity of Dr Christopher Nave, Non-Executive Director of the Company	Ordinary	181,253,973 99.00%	1,433,730 0.78%	0 0.00%	409,869 0.22%	181,253,973 99.00%	1,433,730 0.78%	409,869 0.22%
Item 11 Approval of amendment to Amended and Restated Certification of Incorporation to reflect Delaware law provisions regarding exculpation of officers	Ordinary	203,016,798 99.51%	47,150 0.02%	0 0.00%	956,750 0.47%	203,016,798 99.51%	47,150 0.02%	956,750 0.47%